HNGE Hinge Health, Inc.
Services-Computer Processing & Data Preparation · NYSE · SEC CIK 1673743 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY49.9%
TTM net income YoY131.6%
TTM EPS YoY146.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin85.7%
Operating margin18.7%
Net margin21.0%
FCF margin40.2%
EBITDA margin19.1%
Returns
ROE66.3%
ROA20.5%
ROIC (approx.)869.6%
Asset turnover0.97x
Leverage & solvency
Liabilities / assets65.7%
Debt / equity0.00x
Current ratio1.04x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.92x
Accruals ratio-18.8%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $587.86M | $390.40M | $292.73M |
| Cost of revenue | $119.64M | $90.50M | $98.55M |
| Gross profit | $468.22M | $299.90M | $194.18M |
| R&D expense | $368.14M | $100.84M | $110.06M |
| SG&A expense | $329.50M | $63.91M | $67.02M |
| Operating income | -$546.37M | -$31.91M | -$130.51M |
| Pretax income | -$527.26M | -$11.26M | -$108.55M |
| Income tax | $998,000 | $677,000 | -$405,000 |
| Net income | -$528.26M | -$11.93M | -$108.14M |
| EBITDA | -$541.24M | -$25.96M | -$124.89M |
| EPS (basic) | -7.77 | -0.88 | -8.31 |
| EPS (diluted) | -7.77 | -0.88 | -8.31 |
| Weighted avg. shares (diluted) | 54.58M | 13.56M | 13.02M |
| Banking | |||
| Provision for credit losses | $3.06M | $5.41M | $4.86M |
| Balance sheet | |||
| Cash & equivalents | $208.00M | $302.59M | $234.95M |
| Short-term investments | $155.87M | $165.79M | — |
| Receivables | $66.06M | $42.49M | — |
| Inventory | $15.64M | $10.87M | — |
| Current assets | $533.90M | $583.45M | — |
| PP&E, net | $10.49M | $7.38M | — |
| Goodwill | $64.10M | $61.61M | — |
| Intangibles | $2.51M | $1.81M | — |
| Total assets | $744.76M | $673.26M | — |
| Current liabilities | $362.41M | $249.30M | — |
| Total liabilities | $366.23M | $256.56M | — |
| Shareholders' equity | $178.66M | -$434.57M | -$423.99M |
| Shares outstanding | 0 | 16.38M | — |
| Cash flow statement | |||
| Operating cash flow | $171.44M | $49.00M | -$63.91M |
| Capital expenditure | $708,000 | $1.04M | $1.98M |
| Free cash flow | $170.73M | $47.96M | -$65.89M |
| Investing cash flow | -$113.76M | $18.31M | $1.50M |
| Financing cash flow | -$150.47M | -$2.20M | -$3.00M |
| Depreciation & amortization | $5.13M | $5.95M | $5.63M |
| Stock-based compensation | $643.01M | $739,000 | $1.65M |
| Share buybacks | $65.03M | $0 | $0 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.